# Overtreatment

Source: https://onco.cc/terms/overtreatment/  
OnCo record `overtreatment` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Treating a cancer that was never going to cause trouble. It is the harm that overdiagnosis causes: the diagnosis itself does not leak urine or end erections, the operation does. Published estimates of how much prostate cancer is overdiagnosed range from under 2 percent to two thirds, and the range is a fact about the methods, not about the disease.

## Summary

Overdiagnosis is finding a cancer that would never have caused symptoms or death; overtreatment is what turns that into an injury. The distinction matters because only one of the two can be fixed once the test has been done. An overdiagnosed cancer managed by active surveillance costs anxiety and appointments; the same cancer taken to radical prostatectomy or radical radiotherapy costs the continence and sexual function of a man who was never at risk from it.

The range, and why it is a range. Loeb and Etzioni reviewed the primary data across epidemiological, clinical and autopsy studies and found overdiagnosis estimates from 1.7 percent to 67 percent. Four incompatible methods sit behind that spread: lead-time modelling, which gave 23 to 42 percent of screen-detected cancers in the United States calibration and 66 percent in the Rotterdam one (Draisma); excess incidence against a pre-screening baseline, which is how Welch and Albertsen counted an additional 1,305,600 United States diagnoses and 1,004,800 definitive treatments between 1986 and 2005, and concluded that more than 20 men were diagnosed for each man who experienced the presumed benefit; counting low-grade minimal tumours in prostatectomy specimens, which gives 1.7 to 46.8 percent; and autopsy series, which find prostate cancer in 18.5 to 38.5 percent of men who died of something else. Each method answers a different question, each depends on the background incidence of the population it was measured in, and none of them is wrong. A single overdiagnosis percentage quoted without its method and its population is not a meaningful figure.

The harm side is better measured than the numerator. The 2018 United States task force statement puts it in units a man can weigh: screening men aged 55 to 69 may prevent about 1.3 prostate cancer deaths and about 3 cases of metastatic disease per 1,000 men screened over about 13 years, while about 1 in 5 men who have radical prostatectomy develop long-term urinary incontinence and 2 in 3 experience long-term erectile dysfunction. Those harms fall only on the men who are treated, which is why the size of the overtreatment problem depends on how many screen-detected cancers are managed conservatively, and why the rise of active surveillance, magnetic resonance imaging triage before biopsy and risk-banded guidelines (NICE NG131 offers active surveillance first in Cambridge Prognostic Group 1) changes the answer without changing the test.

## Fields

- Kind: Term
- Last checked: 2026-09-25
- Also known as: over-treatment; overtreatment of prostate cancer; unnecessary treatment; treatment of overdiagnosed cancer
- Tags: gu; prostate-glossary

## Notes

- Why the estimates differ by method, in one line each. Lead-time modelling asks what fraction of screen-detected cancers would not have surfaced before death, and depends on the assumed natural history and on competing mortality. Excess incidence compares diagnoses after screening began against a pre-screening baseline, and depends on how much of the rise was incidence rather than detection. Prostatectomy series count low-grade minimal tumours in specimens, and depend on the threshold for minimal. Autopsy series count cancer in men who died of other causes, and measure reservoir rather than overdiagnosis, because some autopsy-detected cancer is high grade and would have surfaced.
- Overtreatment is not a synonym for treatment you regret. It is a population measure: it counts the treatments given to cancers that would never have become symptomatic, and it can only be estimated in aggregate. No test tells an individual man that his own cancer is one of them, which is why the practical answer is a strategy that defers treatment safely rather than a better estimate.
- The older figures are historical. The Loeb review was published in 2014, before magnetic resonance imaging triage before biopsy and before active surveillance reached its current share of low-risk management, and the review itself records contemporary international studies showing increasing use of conservative management.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Unnecessary_health_care
- Loeb et al., European Urology 2014: overdiagnosis and overtreatment of prostate cancer: https://doi.org/10.1016/j.eururo.2013.12.062
- Draisma et al., Journal of the National Cancer Institute 2009: lead time and overdiagnosis in prostate-specific antigen screening, importance of methods and context: https://doi.org/10.1093/jnci/djp001
- Welch and Albertsen, Journal of the National Cancer Institute 2009: prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005: https://doi.org/10.1093/jnci/djp278
- US Preventive Services Task Force, JAMA 2018: screening for prostate cancer, recommendation statement: https://doi.org/10.1001/jama.2018.3710
- NICE NG131: prostate cancer, diagnosis and management (recommendations): https://www.nice.org.uk/guidance/ng131/chapter/Recommendations

## Connected records

- terms: [Active surveillance and observation](https://onco.cc/terms/active-surveillance-term/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/), [Lead time, and lead-time bias](https://onco.cc/terms/lead-time-bias/), [Number needed to screen (and number needed to diagnose)](https://onco.cc/terms/number-needed-to-screen/), [Other-cause mortality](https://onco.cc/terms/other-cause-mortality/), [Overdiagnosis](https://onco.cc/terms/overdiagnosis/), [Quality of life](https://onco.cc/terms/quality-of-life/), [Screening](https://onco.cc/terms/screening/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/), [PSA and MRI-first prostate cancer screening](https://onco.cc/technologies/prostate-screening-psa-mri/)
- key papers: [Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context](https://onco.cc/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/), [Overdiagnosis and overtreatment of prostate cancer](https://onco.cc/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/), [PIVOT: follow-up of prostatectomy versus observation for early prostate cancer](https://onco.cc/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/), [Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005](https://onco.cc/key-papers/paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009/), [SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up](https://onco.cc/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/), [USPSTF 2012: screening for prostate cancer, recommendation statement (grade D)](https://onco.cc/key-papers/paper-moyer-uspstf-prostate-screening-ann-intern-med-2012/), [USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)](https://onco.cc/key-papers/paper-uspstf-prostate-screening-jama-2018/)
- cancers: [Localised prostate cancer, intermediate risk](https://onco.cc/cancers/prostate-intermediate-risk/), [Localised prostate cancer, very low and low risk](https://onco.cc/cancers/prostate-low-risk/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- bottlenecks: [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- ideas: [Judge a prostate screening programme on metastatic presentation, not on incidence or mortality](https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/)

---
JSON: https://onco.cc/api/v1/entities/overtreatment.json